Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 2c

November 15, 2016 9:19 AM EST
Get Alerts BCLI Hot Sheet
Trade BCLI Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11).

As of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment